COMMUNIQUÉS West-GlobeNewswire

Cannabix Marijuana Breath Test Clears Key Regulatory Milestone: Handheld Breath Collection Unit (BCU) Passes FCC Electronic Emissions Testing
09/12/2025
VANCOUVER, British Columbia, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) is pleased to announce that the Cannabix Breath Collection [...]
Cedar Gate Introduces Next-Generation Solutions for Prospective Bundled Payment Models
09/12/2025
GREENWICH, Conn., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Cedar Gate Technologies (Cedar Gate), an IQVIA business and a leader in value-based care technology with over 40 years of experience in bundled payments, has launched [...]
Clene to Present at the Emerging Growth Conference
09/12/2025
SALT LAKE CITY, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company [...]
Akari Therapeutics Highlights Preclinical Data Demonstrating Therapeutic Potential of Lead Candidate, AKTX-101, for Hard-to-Treat K-Ras Mutant Pancreatic Cancer
09/12/2025
Data highlights the ability of Akari’s Trop2 ADC, AKTX-101, to kill K-Ras G12V mutated cancer cell lines in preclinical models, potentially addressing one of the most lethal cancers with the lowest survival rates The K- [...]
Novo Nordisk has completed its acquisition of Akero Therapeutics
09/12/2025
Bagsværd, Denmark and South San Francisco, CA, US, 9 December 2025 – Novo Nordisk and Akero Therapeutics Inc. (“Akero”) (Nasdaq: AKRO) today announced that Novo Nordisk’s acquisition of Akero, announced on 9 October [...]
Zelluna ASA: Cancellation of subsequent repair offering
09/12/2025
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. [...]
Osivax Completes Enrollment in Phase 2b Asuniva Trial Evaluating Broad-Spectrum Influenza A Vaccine Candidate OVX836
09/12/2025
Target enrollment of 2,850 healthy volunteers completed across multiple European countries Topline data read-out expected by mid-2026, subject to influenza circulation during the winter season Lyon, France and Liège, [...]
European Commission approves Roche’s Gazyva/Gazyvaro for adults with active lupus nephritis
09/12/2025
Approval based on phase II NOBILITY and phase III REGENCY studies showing superiority of Gazyva/Gazyvaro over standard therapy alone 1,2 Gazyva/Gazyvaro is the only anti-CD20 antibody to demonstrate a benefit in a [...]
Roche launches new PCR test to help improve diagnostic accuracy for women affected by vaginitis in countries following the CE Mark
09/12/2025
The new PCR test aids in the diagnosis of infectious causes of vaginitis through the detection of bacteria associated with bacterial vaginosis and yeast associated with candida vaginitis. The test will help improve [...]
OSE Immunotherapeutics dévoile son plan stratégique 2026 - 2028 axé sur quatre leviers de création de valeur
09/12/2025
OSE Immunotherapeutics dévoile son plan stratégique 2026 - 2028 axé sur quatre leviers de création de valeur Finalisation de la phase 3 de Tedopi® dans le cancer du poumon non à petites cellules Une ou deux nouvelles [...]
OSE Immunotherapeutics Unveils 2026–2028 Strategic Plan With Four Opportunities for Value Creation
09/12/2025
OSE Immunotherapeutics Unveils 2026–2028 Strategic Plan With Four Opportunities for Value Creation Completion of Tedopi’s phase 3 in Non-Small Cell Lung Cancer One or two new rare/specialty indications for Lusvertikimab [...]
Scancell updated Phase 2 data shows continued improvement in progression free survival with iSCIB1+ in patients with first line advanced melanoma
09/12/2025
Progression free survival (PFS) of 74% at 16 months compares favourably to standard of care PFS of 50% at 11.5 months 1 Strong PFS consistent across key subgroups Reaffirms selection of iSCIB1+ and target HLA population [...]
Enterome presents strengthened interim Phase 2 results for lead OncoMimics™ immunotherapy EO2463 to treat follicular lymphoma at ASH
09/12/2025
New data show 100% (6/6) objective response rate (ORR) with EO2463 in previously untreated patients with follicular lymphoma needing treatment in combination with rituximab (SIDNEY Cohort 3) Of the 6 patients, 5 had a [...]
Actimed Therapeutics to Highlight Advancing Clinical Pipeline with New Data Presentations at 18th Annual Conference on Sarcopenia, Cachexia, and Wasting Disorders
09/12/2025
London, UK – 9 th December 2025. Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and other muscle [...]
Relation announces strategic collaboration with Novartis to advance therapeutics for atopic diseases
09/12/2025
LONDON, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Relation today announced a multi-program, strategic collaboration with Novartis to discover and advance novel targets for atopic diseases. Under the terms of the agreement, [...]
Relation announces further $26 million investment
09/12/2025
LONDON, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Relation today announced a further $26 million investment from existing investors NVentures (NVIDIA’s venture capital arm) and leading deeptech investors DCVC and Magnetic [...]
Latest Data of InnoCare’s Novel BCL2 Inhibitor Presented at the 67th Annual Meeting of the American Society of Hematology (ASH)
09/12/2025
BEIJING, Dec. 08, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that three studies [...]
Imviva Biotech Presents Validating Data for CAR-T Cell Therapies CTD402 and CTA311 in Five Presentations at the 67th American Society of Hematology Annual Meeting
09/12/2025
Poster presentation highlights promising results from Phase 1b/2 TENACITY-01 study of CTD402 in T-Cell and myeloid leukemias Findings underscore potential to address unmet needs in multiple hematological malignancies, [...]
“LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Included in China’s Commercial Insurance Innovative Drug List
09/12/2025
TOKYO and CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: [...]

Pages